The Moving Average Convergence Divergence (MACD) for FLMNY turned positive on December 03, 2024. Looking at past instances where FLMNY's MACD turned positive, the stock continued to rise in of 20 cases over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 27, 2024. You may want to consider a long position or call options on FLMNY as a result. In of 23 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.873) is normal, around the industry mean (23.300). P/E Ratio (36.765) is within average values for comparable stocks, (83.485). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.016) settles around the average of (0.018) among similar stocks. P/S Ratio (2.239) is also within normal values, averaging (43.338).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. FLMNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FLMNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
Industry MedicalSpecialties
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
WIGTX | 14.20 | 0.02 | +0.14% |
Seven Canyons World Innovators Instl | |||
MNOPX | 29.94 | 0.03 | +0.10% |
Morgan Stanley Inst International Opp R6 | |||
HLIZX | 26.92 | N/A | N/A |
Harding Loevner International Eq Instl Z | |||
DESSX | 25.36 | -0.11 | -0.43% |
DWS ESG Core Equity S | |||
MLPTX | 9.52 | -0.05 | -0.52% |
Invesco SteelPath MLP Select 40 Y |
A.I.dvisor indicates that over the last year, FLMNY has been closely correlated with KSRBF. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if FLMNY jumps, then KSRBF could also see price increases.
Ticker / NAME | Correlation To FLMNY | 1D Price Change % | ||
---|---|---|---|---|
FLMNY | 100% | N/A | ||
KSRBF - FLMNY | 69% Closely correlated | N/A | ||
CNVVF - FLMNY | 36% Loosely correlated | N/A | ||
BDSX - FLMNY | 22% Poorly correlated | +1.46% | ||
NURO - FLMNY | 20% Poorly correlated | -3.33% | ||
JNDOF - FLMNY | 13% Poorly correlated | N/A | ||
More |